Home › Adenocarcinoma esofageo › Texas
Studi clinici su Adenocarcinoma esofageo nello stato di Texas
19 studi su Adenocarcinoma esofageo cercano partecipanti presso sedi nello stato di Texas.
Città nello stato di Texas
Testo ufficiale dello studio (inglese)
Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial
- Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston
- Ben Taub General Hospital, Houston
In reclutamentoFase 2/3
Età 18 e oltre · Tutti i sessi · Aggiornato il 2 ott 2026 · NCT06203600mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma
- Parkland Memorial Hospital, Dallas
- UT Southwestern Simmons Cancer Center - RedBird, Dallas
- UT Southwestern/Simmons Cancer Center-Dallas, Dallas
- e altri 3
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 2 ott 2026 · NCT05677490A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
- The University of Texas MD Anderson Cancer Center - Conroe, Conroe
- University of Texas MD Anderson Cancer Center, Houston
- The University of Texas, MD Anderson Cancer Center - West Houston, Houston
- e altri 3
In reclutamentoFase 1
Età 18 e oltre · Tutti i sessi · Aggiornato il 1 ott 2026 · NCT07090499Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
- The Methodist Hospital Research Institute, Houston
- The University of Texas MD Anderson Cancer Center, Houston
In reclutamentoFase 1/2
Età 18 e oltre · Tutti i sessi · Aggiornato il 30 set 2026 · NCT06324357A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204)
- Texas Oncology - Amarillo Cancer Center, Amarillo
- Texas Oncology-Austin Central, Austin
- Texas Oncology, Beaumont
- e altri 4
In reclutamentoFase 2/3
Età 18 e oltre · Tutti i sessi · Aggiornato il 30 set 2026 · NCT07221149Symbiotic-GI-16: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Gastroesophageal Cancer
- US Oncology Investigational Products Center (IPC), Irving
In reclutamentoFase 2/3
Età 18 e oltre · Tutti i sessi · Aggiornato il 28 set 2026 · NCT07392892A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors
- START Dallas Fort Worth, Fort Worth
- MD Anderson, Houston
- NEXT Oncology Houston, Houston
- e altri 1
In reclutamentoFase 1
Età 18 e oltre · Tutti i sessi · Aggiornato il 28 set 2026 · NCT07277413Itraconazole in Combination With Ablation for the Prevention of Esophageal Cancer in Patients With High-risk Barrett's Esophagus
- Baylor University Medical Center, Dallas
In reclutamentoFase 2
Età 18 e oltre · Tutti i sessi · Aggiornato il 14 set 2026 · NCT06732388Surveillance vs. Endoscopic Therapy for Barrett's Esophagus With Low-grade Dysplasia
- Baylor University Medical Center, Dallas
- The University of Texas MD Anderson Cancer Center, Houston
In reclutamento
Età da 18 a 89 · Tutti i sessi · Aggiornato il 11 set 2026 · NCT05753748A Study of KK2269 in Adult Participants With Solid Tumors
- The University of Texas Southwestern Medical Center, Dallas
In reclutamentoFase 1
Età 18 e oltre · Tutti i sessi · Aggiornato il 10 set 2026 · NCT06266299Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2
- Research Site, Dallas
- Research Site, Dallas
- Research Site, Houston
- e altri 1
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 9 set 2026 · NCT07431281A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors
- Normunity Investigational Site, Dallas
- Normunity Investigational Site, Houston
- Normunity Investigational Site, San Antonio
In reclutamentoFase 1
Età 18 e oltre · Tutti i sessi · Aggiornato il 18 ago 2026 · NCT07182149A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
- Texas Oncology - West Texas, Amarillo
- Texas Oncology, P.A., Dallas
- Texas Oncology Gulf Coast, Pearland
In reclutamentoFase 1/2
Età 18 e oltre · Tutti i sessi · Aggiornato il 5 ago 2026 · NCT06330064A Study of CHS-114 (Tagmokitug) in Combination With Toripalimab and/or Other Treatments in Participants With Advanced Solid Tumors
- Texas Oncology - Central South, Austin
- START San Antonio, LLC., San Antonio
In reclutamentoFase 1
Età 18 e oltre · Tutti i sessi · Aggiornato il 15 lug 2026 · NCT06657144A Study of Sigvotatug Vedotin in Advanced Solid Tumors
- Oncology Consultants, PA, Houston
- Oncology Consultants, PA., Houston
- The University of Texas M.D. Anderson Cancer Center, Houston
- e altri 5
In reclutamentoFase 1
Età 18 e oltre · Tutti i sessi · Aggiornato il 6 lug 2026 · NCT04389632First-in-Human Study of PLX-61639 in Locally Advanced or Metastatic Solid Tumors
- Research Site, San Antonio
In reclutamentoFase 1
Età 18 e oltre · Tutti i sessi · Aggiornato il 12 giu 2026 · NCT07284186A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-130037 in Participants With Advanced Solid Tumors
- MDACC, Houston
- NEXT Dallas, Irving
In reclutamentoFase 1
Età 18 e oltre · Tutti i sessi · Aggiornato il 8 mag 2026 · NCT05954312Chemotherapy With or Without Radiation or Surgery in Treating Participants With Oligometastatic Esophageal or Gastric Cancer
- M D Anderson Cancer Center, Houston
In reclutamentoFase 2
Età da 18 a 79 · Tutti i sessi · Aggiornato il 15 apr 2026 · NCT03161522A Phase II Trial to Evaluate the Effect of Itraconazole on Pathologic Complete Response Rates in Resectable Esophageal Cancer
- VA North Texas Health Care System Dallas VA Medical Center, Dallas, TX, Dallas
- Michael E. DeBakey VA Medical Center, Houston, TX, Houston
In reclutamentoFase 2
Età 18 e oltre · Tutti i sessi · Aggiornato il 5 nov 2025 · NCT05563766Fonte: ClinicalTrials.gov, dati recuperati il 5 ott 2026. Ogni studio stabilisce i propri criteri di idoneità; è il team di ricerca a decidere chi può partecipare.